NANOSTRING SERVICES – NOW OFFERED AT PROPATH
DNA + RNA + Protein
Profile combinations of targets up to 800-plex from a single sample.
Pre-matched multi-analyte assays for Immuno-Oncology, Solid Tumor, and Lung Tumor Profiling.
PROPATH RECEIVES THE QUEEN’S AWARD FOR ENTERPRISE
The UK Prime Minister’s office has recently announced that Propath, a specialist in molecular pathology for biopharmaceutical research and development, has received the Queen’s Award for Enterprise in recognition of the company’s exceptional contribution to the Global Life Sciences sector.
As the UK’s most prestigious business accolade, the Queen’s Award is presented to those companies that demonstrate outstanding growth and achievement in business. Propath was selected to receive the award based on its contribution to the advancement of novel immunotherapies, and success in delivering specialist research services to the global biopharmaceutical sector.
PROPATH: THE TRUSTED SPECIALIST IN MOLECULAR PATHOLOGY FOR BIOPHARMACEUTICAL R&D
For confidential advice on your specific project, please feel free to contact us.
PROPATH: DISCOVERY IS IN THE DETAIL
Pharmaceutical research demands the highest level of scientic rigour and focus on the smallest of details. And for 35 years, Propath has been doing just that: conducting GLP and GCP regulated research studies on behalf of its clients – focusing meticulously on every detail, whilst our experienced and committed scientists apply ever more innovative research techniques to generate reliable study outcomes.
In that time, many of our clients have pioneered innovative new therapies, especially in the promising field of immuno-oncology – which in turn have improved the quality of patients’ lives worldwide. Sponsors have made increasing demands on our services while regulatory requirements have become ever more exacting.
Propath has responded by building a team of highly motivated scientists and technicians, developing a culture of accuracy and QA compliance, and investing in the most advanced analytical technologies available. We have developed a vision of the service that matches our clients’ ambitions to be at the forefront of advances in novel therapies... and delivered that vision.
Today, Propath is one of Europe’s leading specialists in molecular pathology for biopharmaceutical research and development.
We are trusted by some of the world’s best-known bio-pharmaceutical businesses, as well as a host of spin offs and SMEs pioneering exciting new developments. They look to us to deliver robust results – rapidly and cost effectively. Our rigorous attention to the minutest detail ensures total compliance and consistent outcomes – every time.
Thousands of successfully conducted studies have demonstrated our professionalism and our commitment to clients. And our vision for the future will ensure that Propath will continue to be the very best at what we do.
A Selection of Recent Studies
Case study 1.0
Immunohistochemistry and quantitative digital image analysis
The aim of this study was to utilise IHC and quantitative digital image analysis techniques to evaluate expression of PD-L1, MHC-1, Acetyl Histone H3 and Acetyl-α-Tubulin within the viable tumour region of mouse syngeneic cell line derived xenograft tumour tissue samples. Read more
Case study 2.0
Multiplex / Dual marker IHC staining
Scientists at Propath were asked to develop and optimise a dual IHC stain for immune cell markers FoxP3 and CD4 in human tonsil tissue, that could subsequently be used on human samples from a clinical trial. Multiplex stains are technically complex where multiple parameters require balancing to produce a clear, precise and intense stain for the two or more test articles. Read more
Case study 3.0
Therapeutic antibody tissue cross reactivity assessment
The objective of this GLP tissue cross reactivity (TCR) study was to assess the potential cross reactivity of a novel antibody-drug conjugate in a panel of frozen human tissues and blood smears from three unrelated donors. Propath adopted a two-phase approach to this study: a non-GLP method development and validation phase to produce a robust, reliable immunohistochemical (IHC) method; followed by GLP staining and pathology review of the stained tissue panel. Read more